Literature DB >> 30639950

Clinical effectiveness of novel rosacea therapies.

Brittany Feaster1, Abigail Cline2, Steven R Feldman3, Sarah Taylor1.   

Abstract

Rosacea is a common inflammatory skin disease that is difficult to manage because of the unknown etiology and due to its variable manifestations. These facts and the few new available treatment options make it difficult to select a really effective treatment. This review aims to assess the efficacy and safety of novel treatment options for rosacea. The topical alpha adrenergic agonist oxymetazoline reduces rosacea-related erythema. Topical ivermectin improves lesion count, inflammation, and maintenance of remission of rosacea compared to topical metronidazole. Procedural therapies including pulsed dye laser, radiofrequency, and dual frequency ultrasound are promising as both monotherapies or in combination. Although there are several effective treatment modalities for rosacea management, treatments options should be tailored for the specific clinical scenario.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30639950     DOI: 10.1016/j.coph.2018.12.001

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  3 in total

1.  A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections.

Authors:  Daniele Maggioni; Annamaria Cimicata; Antonella Praticò; Roberta Villa; Ferdinando Marco Bianchi; Silvia Busoli Badiale; Claudio Angelinetta
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-04-21

2.  Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.

Authors:  James Q Del Rosso; Sam Brantman; Hilary Baldwin
Journal:  Dermatol Ther       Date:  2021-12-02       Impact factor: 3.858

Review 3.  Conventional and Novel Treatment Modalities in Rosacea.

Authors:  Burhan Engin; Defne Özkoca; Zekayi Kutlubay; Server Serdaroğlu
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.